Icosabutate is a synthetic ω-3 polyunsaturated fatty acid derived from eicosapentaenoic alcohol and 2-bromo butyric acid. It was designed to resist β-oxidation and complex lipid incorporation and increase efficacy in fatty acid-responsive intracellular signaling systems.^1,2 In a clinical trial, oral administration of icosabutate (600 mg) significantly reduced triglyceride, very low-density lipoprotein cholesterol, and Apo c-III levels in patients with very high triglyceride levels.^1,2

≥95%